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Lassa fever is an ancient disease and is endemic in most West African countries. Importantly, Lassa 
fever is a dangerous and virulent disease because it exerts deleterious effects on many vital organs 
in the body. Due to its endemic nature and the yearly occurrence of the disease in terms of infection 
and mortality cases in some West African countries, specifically Nigeria, there is need to reexamine 
and reemphasize viable prevention alternatives. On this backdrop, this review provides a broad 
overview of Lassa fever, with the main emphasis on preventive measures. Infection with the Lassa 
fever virus has severe consequences on health; in this respect, multifaceted preventive measures 
that ensure and guarantee no contact with multimammate rodents should be adopted. Furthermore, 
contact with the feces and urine of multimammate rats should be avoided, personal hygiene should 
always be practiced, environmental sanitation should be ensured and carried out often, the 
consumption and eating of rats should be discouraged, abolished and ultimately stopped, and food 
containers should always be kept tight and closed. 
 
(Ayenigbara IO, Ayenigbara GO, Abulogbon MO, Laleye OF, Akinyemi B. The Endemicity of Lassa 
Fever in West Africa; Appropriate Mitigative Measures. SEEMEDJ 2021; 5(1); 25-36) 
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Introduction 
Lassa fever develops through the infection by 
the Lassa virus (LASV) (1, 2). Although the disease 
was first discovered in the early 1950s, the 
causative agent was not recognized or known 
until the late 1960s. The virus that causes the 
disease belongs to the family of Arenaviridae 
viruses (3). The history of Lassa fever dates back 
to the 1950s, when the first case was recorded in 
Nigeria, Borno State, in the town of Lassa, after 
which the disease was named Lassa fever in 
1969 (3). Presently, the disease is endemic in 
West African countries because of the yearly 
cases of infection and death (1, 4-6). Numerical 
estimates indicate that confirmed cases of Lassa 
fever range between 350000 and 550000, and 
over 5000 deaths per year are recorded globally 
(3). 
Hosts of the Lassa virus are infected 
multimammate rats and rodents, and humans 
usually become infected with the virus due to 
contact with urine or feces of infected animals 
(3). The issue of Lassa fever is a yearly 
phenomenon in Nigeria, and the surge of 
infections in humans is usually seen in the dry 
season between December and April, due to the 
reproduction cycle of new multimammate rats 
and rodents in the rainy season (7). The Lassa 
virus is easily transmitted and highly contagious, 
and the disease it causes is deleterious because 
it has severe health consequences for the whole 
system (3). Once a person is infected with the 
Lassa virus, the virus weakens organs in the 
body, consequently resulting in organ 
malfunctions and depletion of the whole system.  
In regard to its public health importance, Lassa 
fever is a yearly phenomenon in endemic 
countries because of the rapid multiplication of 
the virus in the newly infected multimammate 
rats and rodents, which, once infected, continue 
to shed the virus in their feces and urine 
throughout their life (7). Although Lassa fever 
may not be completely eradicated due to 
peculiar reasons and lack of existing vaccines 
against the causative virus, transmission of the 
Lassa virus could however be diminished and 
absolutely prevented. Hence, this synopsis 
presents detailed preventive measures against 
Lassa fever. 
Sources of Information 
The review focuses on workable prevention 
alternatives against Lassa fever. The literature 
review was purposely selected with keywords 
on the topic of discourse from PubMed, Google 
Scholar and SpringerLink databases. All eligible 
studies included are clinical trials, meta-
analyses, randomized controlled trials, 
systematic and review articles on the topic of 
discourse. Furthermore, major international and 
national health agencies’ databases were 
searched to find valuable information for the 
review. 
Biological Description of the Lassa 
Virus 
Lassa viruses are typically enclosed, single-
stranded, bisegmented and ambisense RNA in 
nature (8). Their genome is contained in two RNA 
segments that code for two proteins each, one 
in each sense, for a total of four viral proteins. 
The large segment encodes a small zinc finger 
protein (Z), which regulates transcription and 
replication, and the RNA polymerase (L) (9). The 
small segment encodes the nucleoprotein (NP) 
and the surface glycoprotein precursor (GP) or 
the viral spike, which is proteolytically cleaved 
into the envelope glycoproteins GP1 and GP2 
that bind to the alpha-dystroglycan receptor and 
mediate host cell entry (10). 
Lassa fever causes hemorrhagic fever 
frequently shown by immunosuppression. The 
Lassa virus replicates very rapidly and 
demonstrates temporal control in replication. 
The first replication step is transcription of mRNA 
copies of the negative- or minus-sense genome. 
This ensures an adequate supply of viral 
proteins for subsequent steps of replication, as 
the NP and L proteins are translated from the 
mRNA (9, 10). The positive- or plus-sense 
genome then makes viral complementary RNA 
(vcRNA) copies of itself. In addition, the RNA 
copies are a template for producing negative-
sense progeny, but mRNA is also synthesized 
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from it. The mRNA synthesized from vcRNA is 
translated to make the GP and Z proteins (9, 10). 
This temporal control allows the spike proteins 
to be produced last, and therefore delay 
recognition by the host immune system. 
Nucleotide studies of the genome have shown 
that Lassa fever has four lineages: three found in 
Nigeria and the fourth in Guinea, Liberia, and 
Sierra Leone (11). The Nigerian strains seem 
likely to have been ancestral to the others, but 
further research is needed to substantiate this 
(11). 
The Lassa virus enters the host cell through the 
cell-surface receptor, the alpha-dystroglycan 
(alpha-DG), which is a versatile receptor for 
proteins of the extracellular matrix (10). It shares 
this receptor with the prototypical Old World 
arenavirus, the lymphocytic choriomeningitis 
virus. Receptor recognition depends on specific 
sugar modification of alpha-dystroglycan by a 
group of glycosyltransferases known as the 
LARGE proteins (10). Specific variants of the 
genes encoding these proteins appear to be 
under positive selection in West Africa, where 
Lassa fever is prominent (12). Alpha-
dystroglycan is also used as a receptor by 
viruses of the New World clade Carenaviruses 
(Oliveros and Latino viruses). In contrast, the 
New World arenaviruses of clades A and B, 
which include the important viruses Machupo, 
Guanarito, Junin, and Sabia, in addition to the 
non-pathogenic Amapari virus, use the 
transferrin receptor 1 (12). A small aliphatic amino 
acid at the GP1 glycoprotein amino acid position 
260 is required for high-affinity binding to alpha-
DG. Likewise, GP1 amino acid position 259 also 
appears to be important, since all arenaviruses 
showing high-affinity alpha-DG binding possess 
a bulky aromatic amino acid (tyrosine or 
phenylalanine) at this position (10, 12). Unlike 
most enveloped viruses, which use clathrin-
coated pits for cellular entry and bind to their 
receptors in a pH dependent fashion, Lassa and 
lymphocytic choriomeningitis virus instead use 
an endocytotic pathway independent of clathrin, 
caveolin, dynamin and actin (12). Once they enter 
the cell, the viruses are rapidly delivered to 
endosomes via vesicular trafficking, albeit one 
that is largely independent of the small GTPases 
Rab5 and Rab7. On contact with the endosome 
pH-dependent membrane, fusion occurs and is 
mediated by the envelope glycoprotein, which 
at the lower pH of the endosome binds the 
lysosome protein LAMP1, which results in 
membrane fusion and escape from the 
endosome (12). 
The lifecycle of the Lassa virus is similar to the 
Old World arenaviruses. The Lassa virus enters 
the cell by receptor-mediated endocytosis. The 
specific endocytotic pathway used is still 
unknown, but cellular entry is sensitive to 
cholesterol depletion (13). The receptor used for 
cell entry is alpha-dystroglycan, a highly 
conserved and ubiquitously expressed cell 
surface receptor for extracellular matrix 
proteins. Dystroglycan, which is later cleaved 
into alpha-dystroglycan and beta-dystroglycan, 
is originally expressed in most cells to mature 
tissues, and it provides a molecular link between 
the ECM and the actin-based cytoskeleton (13). 
After the virus enters the cell by alpha-
dystroglycan-mediated endocytosis, the low-
pH environment triggers pH-dependent 
membrane fusion and releases the RNP (viral 
ribonucleoprotein) complex into the cytoplasm. 
Viral RNA is unpacked, and replication and 
transcription commence in the cytoplasm (13). 
As replication starts, both S and L RNA genomes 
synthesize the antigenomic S and L RNAs, and 
from the antigenomic RNAs, genomic S and L 
RNA are synthesized. Both genomic and 
antigenomic RNAs are needed for transcription 
and translation. The S RNA encodes GP and NP 
(viral nucleocapsid protein) proteins, while L 
RNA encodes Z and L proteins. The L protein 
usually represents the viral RNA-dependent 
RNA polymerase (14). When the cell is infected 
by the virus, L polymerase is associated with the 
viral RNP and initiates the transcription of the 
genomic RNA. The 5’ and 3’ terminal 19 nt viral 
promoter regions of both RNA segments are 
necessary for recognition and binding of the viral 
polymerase. Primary transcription first 
transcribes mRNAs from the genomic S and L 
RNAs, which code NP and L proteins, 
respectively (14). Transcription terminates at the 
stem-loop (SL) structure within the intergenomic 
region. Arenaviruses use a cap-snatching 
SEEMEDJ 2021, VOL 5, NO. 1 Lassa Fever in West Africa 
28 Southeastern European Medical Journal, 2021; 5(1) 
 
strategy to gain the cap structures from the 
cellular mRNAs, which is mediated by the 
endonuclease activity of the L polymerase and 
the cap-binding activity of NP. Antigenomic RNA 
transcribes viral genes GPC and Z, encoded in 
genomic orientation, from S and L segments, 
respectively. Antigenomic RNA also serves as 
the template for replication (15). After translation 
of GPC, it is post-translationally modified in the 
endoplasmic reticulum. GPC is cleaved into GP1 
and GP2 at the later stage of the secretory 
pathway. Cellular protease SKI-1/S1P is 
responsible for this cleavage (14). The cleaved 
glycoproteins are incorporated into the virion 
envelope with the virus buds and release from 
the cell membrane (14). 
Brief Pathogenesis of Lassa Fever 
Lassa fever is mostly caught by humans through 
exposure to urine or feces of the host rodents, 
commonly through the contamination of 
uncovered food items at home (3). Additionally, 
the spread of the Lassa fever could occur 
through direct contact between infected 
humans. People who live in overcrowded areas 
or environments where the host rodents are 
abundant, as well as places with a lack of 
standard hygienic measures, are at a higher risk 
of infection with the Lassa virus. Furthermore, 
human-to-human route of Lassa fever 
transmission has been confirmed, which 
correlates with infection cases in healthcare 
workers treating Lassa fever patients. Likewise, 
family members caring for infected relatives can 
be infected with Lassa fever through the human-
to-human route of transmission (3, 16). Presently, 
there is no empirical data about viral shielding in 
human breast milk due to increased and 
elevated viremia (17). 
Symptoms of the disease include a flu-like 
illness characterized by fever, general 
weakness, cough, sore throat, headache, and 
gastrointestinal manifestations. Hemorrhagic 
manifestations include vascular permeability 
(15). Upon entry into the body, the Lassa virus 
infects almost every tissue in the human body. It 
starts with the mucosa, intestines, lungs and the 
urinary system, and then progresses to the 
vascular system (18). The main targets of the 
virus are antigen-presenting cells, mainly 
dendritic and endothelial cells (19). Generally, 
when a pathogen enters a host, the innate 
defense system recognizes the pathogen-
associated molecular patterns (PAMP) and 
activates an immune response (19). One of the 
mechanisms detects double-stranded RNA 
(dsRNA), which is only synthesized by negative-
sense viruses (19). In the cytoplasm, dsRNA 
receptors, such as RIG-I (retinoic acid-inducible 
gene I) and MDA-5 (melanoma differentiation-
associated gene 5), detect dsRNAs and initiate 
signaling pathways that translocate IRF-3 
(interferon regulatory factor 3) and other 
transcription factors to the nucleus (20). 
Translocated transcription factors activate the 
expression of interferons, and these initiate 
adaptive immunity. NP encoded in the Lassa 
virus is essential in viral replication and 
transcription, but it also suppresses the host 
innate IFN response by inhibiting the 
translocation of IRF-3 (20). NP of the Lassa virus 
is reported to have an exonuclease activity to 
only dsRNAs (20). The NP dsRNA exonuclease 
activity counteracts IFN responses by digesting 
the PAMPs, thus allowing the virus to evade host 
immune responses (21). 
Diagnosis of Lassa Fever 
Accurate and rapid diagnosis of Lassa fever is 
especially challenging because of unclear signs 
and symptoms, different variants of the Lassa 
virus present in West Africa, and laboratory 
safety concerns regarding highly virulent 
pathogens (22). Viral culture remains the “best 
standard” for Lassa fever diagnosis across the 
diverse Lassa strains, but requires a clinically 
nonactionable amount of time and safety level-
4 precautions to perform (22). Likewise, nucleic 
acid-based assays have become the clinical 
diagnostic standard and may be performed 
rapidly on inactivated specimens under safety 
level-2 conditions, but may have false-negative 
results due to the high variance among viruses 
(22). Viral antigen assays may provide a rapid 
diagnosis early on during the illness, but may 
miss the diagnosis at later stages, once the 
antigenemia phase has resolved (22). The 
detection of a new IgM antibody response can 
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diagnose Lassa fever, but may miss the 
diagnosis during the early stage of illness, may 
be falsely negative in severe infections where 
patients are unable to mount a serological 
response, and may remain positive for a 
prolonged period, potentially leading to false-
positive results (22). A rise in baseline antibody 
titers between acute- and convalescent-phase 
serum or a positive IgM accompanied by the 
development of a new positive IgG response 
may be more indicative of acute Lassa fever in 
regions where it is endemic than a single positive 
IgM titer (22). 
To sum up, an orthogonal diagnostic system 
employing molecular (PCR-based) and 
immunological (antibody-based) assays 
provides the greatest confidence in a diagnostic 
result for Lassa fever (23). Also, rapid diagnostic 
tests (RDTs) such as lateral flow immunoassays 
(LFIs) can be an important addition to the 
orthogonal system and can significantly reduce 
infections in ongoing outbreaks and in endemic 
areas (23). Furthermore, multiplex, magnetic 
bead-based assays are a significant 
improvement over traditional enzyme-linked 
immunosorbent assays (ELISAs) (23). 
 
Clinical Manifestations of Lassa Fever 
The period between contact with the Lassa virus 
and the appearance of signs and symptoms is 
usually 6 to 20 days (3). There are numerous 
signs and symptoms of Lassa fever, however, 
general weakness, migraine and headache, sore 
throat, muscle pain, chest pain, nausea, 
vomiting, diarrhea, cough, and abdominal pain 
are most commonly reported and seen in 
patients (3, 24). In addition, protein may be seen 
in the urine of Lassa fever patients, and patients 
may also experience shock and seizures, while 
coma could occur in advanced stages of the 
disease due to the absence of treatment (3, 24). 
Although other infectious diseases may present 
with the aforementioned signs and symptoms, it 
is imperative to visit a hospital or a healthcare 
clinic for proper diagnosis and early treatment of 
any diagnosed infection. About 25% of Lassa 
fever survivors have hearing problems, which 
are typically reversible (25, 26). Incidences of hair 
loss during recuperation from Lassa fever have 
been reported, and death often occurs within a 
few days in severe cases of the disease without 
treatment. Clinical presentation of Lassa fever is 
serious in pregnancy, especially in the last stage 
of pregnancy, because the disease usually 
causes miscarriages and stillbirths due to the 
strong affinity of the Lassa virus for fetal tissue 
(3). In addition, once a person is infected with the 
Lassa virus, the virus weakens the organs in the 
body and causes organ malfunctions and 
depletion of the entire system (17, 24). 
 
The Epidemiological Trend of Lassa 
Fever 
The Lassa virus was first identified in the late 
1960s by a healthcare worker in a healthcare 
center in Lassa, a town in Nigeria (4). After 
diagnosis, the contagious Lassa virus was 
confirmed (27). Over the years, Lassa fever has 
spread from the shores of Nigeria, and 
numerous West African countries, such as 
Burkina Faso, Ghana, Togo, Ivory Coast, Benin, 
Liberia, Guinea and Mali, are either Lassa fever-
endemic or have had cases of infection (28-31, 
Table 1). The infection rate of Lassa fever is high 
based on geographic location (i.e. 1.9% in 
developed countries compared to 56% in 
developing countries); likewise, Lassa fever 
caught in hospitals results in more deaths (32, 
33). Furthermore, findings from hospital-based 
serosurveillance related with suspected cases 
of Lassa virus infection revealed that basic 
hygiene measures among medical workers 
resulted in fewer infection cases compared to 
local inhabitants in villages, where basic hygiene 
practices are less common (33). The 
transmission rate of Lassa fever depends on the 
geographic location, with higher frequencies in 
developing countries compared to developed 
countries (34). 
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Table 1. Summary of West African Nations with Lassa Fever Cases, 1962-2018. Adapted from: (3) 
S/N West African countries with at least 
one case of Lassa virus infection 
Endemic West African 
countries with Lassa 
fever 
West African countries reporting 
Lassa fever outbreaks 
1 Mali Nigeria Nigeria 
2 Burkina Faso Guinea Guinea 
3 Ghana Liberia Liberia 
4 Togo Sierra Leone Sierra Leone 
5 Benin   
6 Ivory Coast   
 
Lassa Fever in Nigeria 
As the world battles the current COVID-19 
pandemic, Nigeria faces a double battle with 
two highly contagious viral infections. Many 
years after it was discovered, Lassa fever is still 
a major public health problem in Nigeria (35). The 
aforementioned statement is evidenced by the 
massive outbreak of the disease in 2018 in the 
country, where 18 out of the 36 states of the 
federation were affected by Lassa fever; this 
was the biggest and the worst case of the 
disease in history (36, 37). In this respect, the 
Nigerian health authority declared the disease 
an emergency (38). From the beginning of 2020 
until 26th December, 6732 associated cases of 
Lassa fever were accounted for in Nigeria, and 
1181 samples returned positive from laboratory 
reports (39)d. Furthermore, from the beginning 
of 2020 until the end of 2020, 244 deaths 
occurred in 27 states, and 131 local government 
areas were affected by Lassa fever across the 
federation, while the general case fatality rate 
(CFR) for 2020 was 20.7% (39). Numerical 
estimates also revealed that Edo, Ondo and 
Ebonyi states had altogether 75% of the positive 
cases of Lassa fever in Nigeria for 2020 (39). 
Cases of Lassa fever were evident in virtually all 
age groups; however, the predominant age 
range of people with confirmed infection for 
2020 was 21-30, while the gender ratio for male 
and female was 1:0.9 (39). Due to the 
overburdening effects of the coronavirus 
disease pandemic (COVID-19) on the healthcare 
system, Lassa fever also exerted additional 
effects on health practitioners, because many 
health workers were infected with both diseases 
mistakenly, with more than two deaths recorded 
due to Lassa fever in 2020 (7). Lassa fever 
patients were treated and managed in various 
hospitals and healthcare centers across the 
country, secondary contacts were also 
identified, and follow-ups were done to ensure 
proper tracking and monitoring of the disease 
(39). Lassa fever is predominant in Nigeria and 
the onset of the disease is usually between 
December and June every year. Imperatively, 
the seasonal surge in new Lassa fever infection 
cases and deaths in the whole of Nigeria is a 
cause for concern and ought to be observed 
intently by both national and international health 
authorities (38). In addition, bordering countries, 
for example Togo and Benin, have had imported 
cases of Lassa fever from Nigeria in the past; 
hence, bordering countries should be closely 
monitored as well (38). 
 
Main Emphasis on the Prevention of 
Lassa Fever 
There are no protective vaccines against Lassa 
fever as of 2020 (40). Because of the endemic 
nature of Lassa fever, the disease was listed 
among future causes of disease outbreaks by 
the World Health Organization (41, 42). Lassa 
fever is prevalent in most West African countries 
and results in the deaths of thousands of people 
ever year (3). Due to the exponential rise in 
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mortality and infection cases of Lassa fever in 
the West Africa subregion, especially Nigeria, it 
is imperative to advance and reemphasize 
knowledge about prevention of the disease. 
 
Prevention at Home 
The transmission route of the Lassa virus to the 
secondary host (humans) should be forestalled, 
hindered and disrupted by limiting and reducing 
any exposure or contact with the feces and urine 
of the primary host (rodents) in Lassa fever 
hotspot areas and geographic locations, 
because worthwhile and beneficial efforts 
regarding the prevention of the disease depend 
on sustainable, adequate and proper personal 
and community hygiene efforts (43, Figure 1). 
Furthermore, successful and effective 
preventive measures against Lassa fever in the 
home include keeping edible items in closed, 
tight and clean containers, discarding, disposing 
of or burning waste and refuse far away from 
residential areas, basic personal hygiene 
practices such as washing hands with clean 
running water and soap before handling any 
edible items, immediate cleaning and washing 
of used plates and pots with detergent and 
clean water, tidy arrangement of kitchen utensils 
and other materials in clean and well-ventilated 
cabinets, always keeping kitchen floors clean 
and tidy, and proper disposal of leftover foods. 
In addition, prompt caution and preventive 
measures should be adopted by relatives when 
caring for persons with Lassa fever (3)..
Figure 1. Prevention of Lassa fever at home (self-developed) 
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Prevention at Hospitals 
High safety measures must always be adopted 
by all healthcare workers in different hospitals, 
clinics and healthcare centers, even when the 
diagnosis and cause of infection are unknown. 
Preventive and control safety measures include 
essential hand washing with soap, detergent or 
antiseptic and clean running water, respiratory 
hygiene and the appropriate use of personal 
protective equipment (PPE) (3). Furthermore, all 
rules and guidelines set by the World Health 
Organization for dealing with cases of highly 
infectious diseases should be strictly followed 
by healthcare workers treating Lassa fever 
patients. In addition, proper checking of personal 
protective equipment (PPE) should be ensured 
and the equipment should always be made 
available to healthcare workers in Lassa fever-
prominent areas, such as Nigeria and other 
neighboring countries. Likewise, laboratory 
workers are at a higher risk of Lassa virus 
infection; hence, all Lassa virus samples in the 
laboratory should be handled with extreme care 
and caution.  
In addition, the infection prevention and control 
authorities (IPC) should ensure that healthcare 
centers and laboratories meet the requirements 
for operation, especially in Lassa fever hotspot 
areas (44). It is imperative to ascertain that all 
healthcare centers attending to Lassa fever 
cases operate with the standard achievable 
around the world, and routine IPC training 
should also be made mandatory for all 
healthcare workers handling cases of Lassa 
fever (44). 
 
Prevention among Travelers 
Migrants moving from countries where Lassa 
fever is prominent often transfer and import the 
disease to other locations or regions; this is 
evident in Togo and Benin, since some of the 
reported cases in the two countries were 
imported from Nigeria (38). Strict and continuous 
border checking and inspection of medical 
reports of travelers is paramount. Imperatively, 
all border rules and regulations pertaining to 
infectious disease checking during border 
crossing should be strictly enforced by border 
patrols and healthcare workers stationed at 
border crossings. Likewise, persons visiting 
Lassa fever-endemic nations for vacation should 
visit the respective embassies and consulates in 
the countries they visit in order to get 
information on Lassa fever-prone areas in such 
countries, as well as to get general health 
information on other infectious diseases 
prevalent in such countries. Furthermore, febrile 
migrants who recently returned from Lassa 
fever-predominant areas should urgently visit a 
healthcare clinic or hospital in their current 
location in order to get a proper diagnosis and 
early treatment (45). 
 
Treatment Options for Lassa Fever 
Treatment options for Lassa fever are few and 
treatments are mainly symptomatic (8). 
Management of bleeding and hydration is 
important, particularly in hemorrhagic cases. 
Likewise, pain management through the use of 
opiates is prescribed (8). Due to the permeability 
of blood vessels, pulmonary edema is a 
concern, and fluid infusion must therefore be 
carefully monitored (8). An antiviral drug 
(Ribavirin) offers beneficial effects for Lassa 
fever patients with poor prognoses, and is 
usually reserved for patients with higher Herliver 
enzyme levels (AST value > 150) (8). Even though 
it is a drug with significant side effects, ribavirin 
is the drug of choice in many cases of Lassa 
fever (8, 46). 
 
Recommendations 
Based on this study, the following 
recommendations are made: 
a) Contact with multimammate rats, especially 
their feces and urine, should be avoided. 
b) Personal hygiene, such as hand washing with 
clean running water and antiseptic soap, should 
be practiced at all times. 
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c) Environmental sanitation, such as clearing and 
cleaning of the environment, should be done 
frequently in order to destroy the habitats of 
multimammate rats. 
d) The barbaric act of eating rats should be 
discouraged, abolished and ultimately stopped. 
e) Containers for food items should be kept tight 
and closed at all times to prevent rats from 
accessing them, and any food items with traces 
of rat feces or urine should be discarded 
immediately. 
f) Healthcare workers, especially nurses, doctors 
and laboratory scientists, should follow the basic 
aseptic practices when treating patients 
infected with Lassa fever. 
g) Health education on Lassa fever should be 
intensified for everyone.  
h) The rearing and breading of cats at home should 
be encouraged. This would help reduce the 
population of rats in the environment, especially 
in rural areas.  
 
Conclusions 
 Lassa virus is highly infectious and could 
infect any individual, since no one is immune to 
the disease. Lassa fever is endemic in most West 
African countries, with yearly cases in terms of 
infection and mortality in Nigeria. People at 
severe risk of infection with Lassa fever are 
individuals living in unhygienic and dirty 
environments with overcrowded living 
conditions, because these are the scenarios and 
situations in numerous Lassa fever-endemic 
areas. Health consequences caused by the 
infectious Lassa fever are enormous. In this 
respect, multifaceted preventive measures that 
ensure, encourage and guarantee no contact 
with multimammate rodents and rats should be 
adopted. Furthermore, there should be a strong 
synergy and cooperation between governments 
and border patrol officers of Lassa fever-
endemic areas to work out effective ways to 
minimize the rate of cross-border transmissions 
of the disease. Likewise, major international 
health organizations should help and assist with 
public health experts and personnel, logistic and 
vital information in curtailing the spread of Lassa 
fever in developing countries. 
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